These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 24492928)

  • 1. Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy.
    Choi MR; Solid CA; Chia VM; Blaes AH; Page JH; Barron R; Arneson TJ
    Support Care Cancer; 2014 Jun; 22(6):1619-28. PubMed ID: 24492928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of primary prophylactic granulocyte colony-stimulating factor use in older Medicare patients with cancer receiving myelosuppressive chemotherapy.
    Schenfeld J; Gong T; Henry D; Kelsh M; Gawade P; Peng Y; Bradbury BD; Li S
    Support Care Cancer; 2022 Jul; 30(7):6327-6338. PubMed ID: 35482126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of chemotherapy-induced febrile neutropenia in patients with metastatic cancer not receiving granulocyte colony-stimulating factor prophylaxis in US clinical practice.
    Averin A; Silvia A; Lamerato L; Richert-Boe K; Kaur M; Sundaresan D; Shah N; Hatfield M; Lawrence T; Lyman GH; Weycker D
    Support Care Cancer; 2021 Apr; 29(4):2179-2186. PubMed ID: 32880732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world use of granulocyte colony-stimulating factor in ambulatory breast cancer patients: a cross-sectional study.
    Van Ryckeghem F; Haverbeke C; Wynendaele W; Jerusalem G; Somers L; Van den Broeck A; Vingerhoedt S; Van Belle S
    Support Care Cancer; 2019 Mar; 27(3):1099-1108. PubMed ID: 30099601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
    Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks and consequences of travel burden on prophylactic granulocyte colony-stimulating factor administration and incidence of febrile neutropenia in an aged Medicare population.
    Stephens JM; Bensink M; Bowers C; Hollenbeak CS
    Curr Med Res Opin; 2019 Feb; 35(2):229-240. PubMed ID: 29661043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
    Salmon JP; Smakal M; Karanikiotis C; Wojtukiewicz MZ; Omnes Y; DeCosta L; Wetten S; O'Kelly J
    Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world evaluation of supportive care using an electronic health record text-mining tool: G-CSF use in breast cancer patients.
    van Laar SA; Gombert-Handoko KB; Wassenaar S; Kroep JR; Guchelaar HJ; Zwaveling J
    Support Care Cancer; 2022 Nov; 30(11):9181-9189. PubMed ID: 36044088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy.
    Gawade PL; Li S; Henry D; Smith N; Belani R; Kelsh MA; Bradbury BD
    Support Care Cancer; 2020 Sep; 28(9):4413-4424. PubMed ID: 31919669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study results.
    Catala G; Mebis J; Jerusalem G; Verhoeven D; Awada A; Bols A; Somers L; Van Den Broeck A; Duhoux FP; Machiels JP
    Acta Clin Belg; 2020 Apr; 75(2):128-135. PubMed ID: 30609907
    [No Abstract]   [Full Text] [Related]  

  • 11. Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance From 2014 to 2019.
    Wang CY; Heldermon CD; Vouri SM; Park H; Wheeler SE; Ramnaraign BH; Dang NH; Brown JD
    JAMA Netw Open; 2021 Nov; 4(11):e2133474. PubMed ID: 34812849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey.
    Link H; Kerkmann M; Holtmann L; Ortner P;
    Support Care Cancer; 2019 Apr; 27(4):1459-1469. PubMed ID: 30374765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
    Skedgel C; Rayson D; Younis T
    Support Care Cancer; 2016 Jan; 24(1):387-394. PubMed ID: 26081595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety.
    Mahtani R; Crawford J; Flannery SM; Lawrence T; Schenfeld J; Gawade PL
    BMC Cancer; 2021 May; 21(1):621. PubMed ID: 34044798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.
    Weycker D; Li X; Tzivelekis S; Atwood M; Garcia J; Li Y; Reiner M; Lyman GH
    Support Care Cancer; 2017 Feb; 25(2):439-447. PubMed ID: 27734153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.
    Gerlier L; Lamotte M; Awada A; Bosly A; Bries G; Cocquyt V; Focan C; Henry S; Lalami Y; Machiels JP; Mebis J; Straetmans N; Verhoeven D; Somers L
    BMC Cancer; 2010 Nov; 10():642. PubMed ID: 21092320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2).
    Yokoyama M; Kusano Y; Nishihara A; Inoue N; Nishimura N; Mishima Y; Terui Y; Nukada T; Nomura T; Hatake K
    Support Care Cancer; 2020 Feb; 28(2):571-579. PubMed ID: 31093770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.
    Mitchell S; Li X; Woods M; Garcia J; Hebard-Massey K; Barron R; Samuel M
    J Oncol Pharm Pract; 2016 Oct; 22(5):702-16. PubMed ID: 26769697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
    Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
    Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer.
    Li S; Liu J; Gong T; Guo H; Gawade PL; Kelsh MA; Bradbury BD; Belani R; Lyman GH
    J Geriatr Oncol; 2020 Nov; 11(8):1309-1315. PubMed ID: 32624415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.